Unlearn®, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that Eisai, a leading global research and development-based pharmaceutical company, has joined the company’s world-class syndicate of investors as part of its Series A extension along with Epic Ventures and Alumni Ventures Group. In April 2020, Unlearn announced Series A financing led by 8VC with participation from DCVC, DCVC Bio and Mubadala Capital Ventures. The extension brings the Series A total to $15 million.